Creo Medical Group (AIM:CREO) has entered a non‑binding agreement to sell its entire 49% holding in Creo Medical S.L. to a purchaser owned by Luis Collantes, CEO of Creo Medical S.L., with the indicative enterprise value stated to be in line with CME's carrying value at 31 December 2025 and with consideration expected to be paid in cash at completion.
Creo, a medical device company focused on minimally invasive electrosurgical devices, said the proposed disposal would simplify the Group, crystallise value from its minority investment and strengthen the balance sheet to support its accelerating growth strategy and path to profitability.
"This proposed transaction represents an opportunity to crystallise value from our minority interest in CME at an attractive valuation," said Craig Gulliford, Chief Executive Officer.
The LOI envisages a cash‑free, debt‑free sale based on that indicative valuation subject to customary closing adjustments, and completion is conditional on shareholder pre‑emption processes, satisfactory purchaser due diligence, agreement of definitive documentation and final financing approvals, the company said, adding that on completion Creo will not participate in any future profits or dividends from CME while CME will continue to act as the Group's distributor in key European jurisdictions.
The parties are targeting completion within three months.
